FDA-filed SPL labeling · retrieved through openFDA

Bimatoprost

Bimatoprost is a prostaglandin analog eye medication used to lower elevated eye pressure in open-angle glaucoma and ocular hypertension, and to treat inadequate eyelash growth.

Brand names LumiganLatisseDurystaZolymbus
Drug class Prostaglandin Analog
Rx Forms 4 Routes Ophthalmic · Intracameral · Topical
Dr. Brian Staiger, PharmD, BCPS
Reviewed by Last reviewed Jul 10, 2026
🧬 Where this information comes from Click to expand

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 19 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →

At a glance
Linked label effectiveJul 1, 2024
Clinical labels in scope 19
AvailabilityRx
Earliest approval/marketing year 2001
FDA-listed product records 84
Boxed warningNone found in compared labels
How we combine label and product data →
No current FDA shortage listed · checked Sep 22, 2026
Other forms & routes:
Bimatoprost at a glance The quick version — the full detail is in the Patient Information Guide below.
💊
HelloPharmacist Editorial Team Bottom Line
Bimatoprost is an effective prostaglandin analog used in several forms to lower eye pressure in open-angle glaucoma and ocular hypertension, and to improve eyelash growth in people with sparse lashes. The biggest thing to know is that it can permanently change your eye color and darken the skin around your eyes. Follow your prescriber's guidance on which product to use and how to apply it correctly.

📖 Bimatoprost: Patient Information Guide

A plain-language walkthrough of Bimatoprost — what it treats, how it works, how it’s taken, side effects, warnings and interactions. Tap any section to expand it.

🎯What it's used for

Bimatoprost is available in several products approved for different uses — not every form treats every condition.

  • Lumigan (eye drops): reduces elevated intraocular pressure in open-angle glaucoma or ocular hypertension
  • Zolymbus (eye ointment): reduces elevated intraocular pressure in open-angle glaucoma or ocular hypertension
  • Durysta (intracameral implant): reduces intraocular pressure in open-angle glaucoma or ocular hypertension — given as a one-time implant inside the eye by a clinician
  • Latisse (eye drops applied topically): treats hypotrichosis of the eyelashes — sparse, thin, or short lashes — by increasing their length, thickness, and darkness
  • Bimatoprost ophthalmic solution 0.03%: also approved to treat hypotrichosis of the eyelashes
⚙️How it works

Bimatoprost is a synthetic prostaglandin analog — meaning it's built to mimic natural substances in the body called prostamides. For glaucoma and high eye pressure, it works by opening up the eye's drainage channels (called the trabecular meshwork and uveoscleral routes), letting excess fluid called aqueous humor drain out more easily. Less fluid inside the eye means lower pressure, which protects the optic nerve from damage and helps preserve vision.

💊How it's taken

The right way to take bimatoprost depends on which product your doctor prescribes — do not mix up instructions between products.

  • Lumigan eye drops: one drop in the affected eye(s) once each evening — never more than once daily
  • Zolymbus eye ointment: one drop from a single-dose container in the affected eye(s) once each evening; open and use immediately, then discard the container
  • Latisse / bimatoprost 0.03% for lashes: applied once nightly to the upper eyelid skin at the lash base using a sterile applicator; use a fresh applicator for each eye and discard after use
  • Durysta implant: a one-time procedure performed by a healthcare provider; the implant should not be repeated in the same eye

If you miss a dose of an eye drop or ointment, just continue with your next scheduled dose — don't double up. Always follow your prescriber's specific directions.

🤒Side effects — in detail

The most common side effects affect the eyes and are often mild, but some changes can be permanent.

  • Eye redness (the most common side effect, seen in up to 45% of users)
  • Increased eyelash growth or darkening
  • Eye itching
  • Eye dryness, burning, or foreign body sensation
  • Darkening of the skin around the eye or eyelids (usually reversible when stopped)
  • Darkening or color change of the iris — this may be permanent
  • Eye pain or visual disturbance
  • Colds or upper respiratory infections (about 10% of users)

Seek medical attention if you notice sudden vision changes, signs of eye inflammation (pain, redness, light sensitivity), swelling around the eye, or signs of an allergic reaction such as severe redness or skin rash.

⚠️Warnings & precautions
  • Permanent iris color change: Bimatoprost can cause the iris to become more brown over time. This can affect one or both eyes and may take months to years to appear. It is likely irreversible — meaning it stays even after you stop the medication. If you use it in only one eye, that eye may permanently end up a different color than the other.
  • Eyelid and skin darkening: The skin around the eye and the eyelashes can darken with use. Unlike iris changes, this darkening of the eyelid skin is usually reversible when treatment stops.
  • Unwanted hair growth: If the solution regularly contacts skin outside the upper eyelid (like the cheek), hair may grow in those areas. Careful application and blotting of any excess is important.
  • Eye inflammation: Use with caution if you have active uveitis (inflammation inside the eye) — bimatoprost may worsen it.
  • Macular edema: Swelling at the center of the retina has been reported, especially in people who've had certain eye surgeries or have risk factors. Tell your doctor your full eye history.
  • Interaction with other prostaglandin eye drops: Using bimatoprost alongside another prostaglandin analog can reduce the eye pressure-lowering effect of both.
🔀What it interacts with

Bimatoprost has a few important interactions to be aware of, mostly involving other eye medications.

  • Other prostaglandin analog eye drops (e.g., Lumigan, Travatan, Xalatan): Using bimatoprost alongside another drug in this class can reduce how well either one lowers eye pressure — your doctor needs to know about all eye drops you use.
  • Other topical eye drops in general: If you use more than one eye drop, wait at least 5 minutes between each to avoid washing one out before it works.
  • Soft contact lenses: Some bimatoprost eye drop products contain benzalkonium chloride, a preservative that can be absorbed by soft contact lenses and cause discoloration. Remove lenses before applying drops and wait 15 minutes before putting them back in.

This is not a complete list of interactions. Always talk with your doctor or pharmacist before starting, stopping, or changing any medication.

📋Before taking it
  • Allergy: Do not use bimatoprost if you are allergic to it or to any ingredient in the product.
  • Eye inflammation: Tell your doctor if you have uveitis or other active eye inflammation — bimatoprost may make it worse.
  • Recent eye surgery or lens issues: If you've had lens surgery (aphakia or pseudophakia with a torn capsule) or are at risk for macular edema, discuss this with your doctor first.
  • Pregnancy: There are no adequate studies in pregnant people. Animal studies at high doses showed risks, but those doses were far higher than typical eye drop exposure. Use only if your prescriber decides the benefit justifies the risk.
  • Breastfeeding: It's not known whether bimatoprost passes into human breast milk in significant amounts. Discuss with your doctor.
  • Children: Bimatoprost ophthalmic solution 0.03% has been studied for eyelash growth in children ages 5–17 in certain conditions; discuss pediatric use with a prescriber.
  • Older adults: No significant differences in safety or effectiveness have been seen between older and younger adults.
🚑If you take too much

There is no information on what happens if a person takes too much bimatoprost. If an overdose occurs, treatment is focused on managing whatever symptoms appear — there is no specific antidote. In animal studies, very high oral doses did not cause toxicity, and the amount in one bottle is well below concerning levels even for a child. If you're worried about accidental exposure, contact Poison Control or seek medical advice.

📡Pharmacodynamics — effects in the body

Bimatoprost lowers intraocular pressure by increasing how much fluid drains out of the eye through two routes: the trabecular meshwork and the uveoscleral pathway. For eye drop products, pressure reduction begins about 4 hours after the first dose, with the maximum effect reached within 8 to 12 hours. Using more than one dose per day does not increase the benefit — in fact, it may actually reduce the pressure-lowering effect, which is why once-daily dosing is recommended.

🔬Pharmacokinetics — how your body processes it

When bimatoprost eye drops are applied to the eye, a small amount is absorbed into the bloodstream. Blood levels peak within about 10 minutes of dosing and fall below detectable levels within 1.5 hours in most people — meaning very little drug accumulates in the body over time. Once in the bloodstream, bimatoprost is broken down (metabolized) by the liver through oxidation and other processes. About 67% of the drug is eventually cleared through the urine and 25% through the feces. The elimination half-life (the time it takes for half the drug to leave the blood) is approximately 45 minutes.

📦How to store it

Store at 2°C to 25°C (36°F to 77°F).

📄 Written from Bimatoprost’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Every point is grounded in that labeling — nothing is invented. How we use AI →

🩺 Pharmacist Counseling Corner

Quick, plain-English answers to the questions patients ask most about Bimatoprost — the kind of thing our pharmacy team would talk through with you at the counter.

What is bimatoprost actually used for — I've heard it's for both glaucoma and eyelashes?
That's right — bimatoprost is used for two different things depending on the product. Eye drops like Lumigan, the eye ointment Zolymbus, and the Durysta implant are prescribed to lower eye pressure in people with open-angle glaucoma or ocular hypertension, which helps protect your vision. A different product, Latisse (and generic bimatoprost 0.03%), is applied to the upper eyelid skin to grow longer, thicker, darker eyelashes in people with sparse lashes. Make sure you know which one you've been prescribed and follow the instructions for that specific product.
Will bimatoprost change the color of my eyes?
It can — and this is one of the most important things to know. Bimatoprost can gradually make the iris (the colored part of your eye) more brown over time. This change can take months or even years to show up, and it's likely permanent — meaning it may not go away even if you stop the medication. If you're only using it in one eye, that eye could end up a different color than the other. Your doctor should explain this risk before you start, especially if you have light-colored eyes.
Can bimatoprost cause hair to grow in places I don't want?
Yes, this is something to be careful about — especially with Latisse or bimatoprost solution applied for eyelash growth. If the solution runs onto your cheek or other skin areas repeatedly, it can stimulate hair growth there too. That's why it's so important to apply it only along the upper eyelid margin and to blot any excess right away. Do not apply it to the lower lash line. Darkening of the skin around your eyes is also possible but usually reverses when you stop the medication.
Can I use bimatoprost with other eye drops I already take?
Possibly, but there's an important catch. If you're already using another prostaglandin analog eye drop — like latanoprost or travoprost — adding bimatoprost may actually reduce how well either one lowers your eye pressure. Your doctor needs to know about every eye drop you use. Also, if you're using more than one eye drop at the same time, wait at least 5 minutes between them so each one has a chance to work properly.
I wear contact lenses — is it safe to put them in before using these eye drops?
You should remove your soft contact lenses before applying bimatoprost eye drops. Some products contain a preservative called benzalkonium chloride that can be absorbed by soft lenses and cause discoloration. After you apply the drops, wait at least 15 minutes before putting your contacts back in. Check the packaging of your specific product for this guidance.
Is it safe to use bimatoprost if I'm pregnant or breastfeeding?
This is a conversation to have with your doctor. There are no well-controlled studies in pregnant people. Animal studies at very high doses showed some risks, but those doses were far above what reaches the body through eye drops. Because of the uncertainty, bimatoprost should only be used during pregnancy if your doctor decides the benefit is worth it. For breastfeeding, it's not known whether the medication passes into breast milk in meaningful amounts, so again, check with your prescriber before using it.
Is Bimatoprost available over the counter?
Bimatoprost is dispensed by prescription according to its FDA labeling, so it isn't sold over the counter. Your prescriber and pharmacist will determine if it's appropriate for you.
When was Bimatoprost first available?
Bimatoprost has been available in the United States since at least 2001, based on FDA approval history (Drugs@FDA) and product marketing records.
Who makes Bimatoprost?
Bimatoprost is supplied by 40 manufacturers listed in the FDA NDC Directory, including Allergan, Inc., Somerset Therapeutics, LLC, Alembic Pharmaceuticals Inc..

💬 Answers drafted from Bimatoprost’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Grounded in that labeling — nothing is made up. How we use AI →

🧰 Keep exploring

💊 How Bimatoprost comes

Bimatoprost is available in 4 forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.

Eye drops

In the eye
Brands Latisse Lumigan
How this form is used
What it may be used for
  • Lumigan is used to reduce elevated intraocular pressure in open-angle glaucoma or ocular hypertension
  • Latisse is used to treat hypotrichosis of the eyelashes — increasing their length, thickness, and darkness
  • Bimatoprost ophthalmic solution 0.03% is used to treat hypotrichosis of the eyelashes by increasing their growth
Important instructions
  • Lumigan: instill one drop into the affected eye(s) once daily in the evening; do not use more than once daily
  • Latisse: apply once nightly to the upper eyelid margin at the base of the lashes using the supplied sterile applicator; do not apply to the lower lash line
  • Bimatoprost ophthalmic solution 0.03% for lashes: apply one drop to the sterile applicator and use along the upper eyelid margin nightly; discard applicator after one use per eye
  • If wearing soft contact lenses, remove them before applying eye drops and wait 15 minutes before reinserting
Available strengths 2 strengths
51 FDA-listed product records

Insert or device

By mouth · Intracameral
Brands Durysta
How this form is used
What it may be used for
  • Durysta is used to reduce intraocular pressure in patients with open-angle glaucoma or ocular hypertension
Important instructions
  • Durysta is administered as a single implant injected into the front chamber of the eye by a healthcare provider under sterile conditions
  • Durysta should not be given a second time to an eye that has already received it
Available strengths 1 strength
4 FDA-listed product records

Topical solution

On the skin
Available strengths 1 strength
2 FDA-listed product records

Eye ointment

In the eye
Brands Zolymbus
How this form is used
What it may be used for
  • Zolymbus is used to reduce elevated intraocular pressure in open-angle glaucoma or ocular hypertension
Important instructions
  • Zolymbus: use one drop from the single-dose container into the affected eye(s) once daily in the evening
  • Zolymbus: do not use more than once daily — more frequent dosing may reduce the eye pressure-lowering effect
  • Zolymbus: use the container immediately after opening and discard it along with any remaining contents right after use
  • Zolymbus: if using other topical eye drops at the same time, wait at least 5 minutes between each medication
Available strengths 1 strength
1 FDA-listed product record

📊 Bimatoprost across the U.S. market

How Bimatoprost appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

4
Dose forms
40
Manufacturers
5
Brand names
84
FDA-listed product records
2001
First marketed

FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

Also listed with the FDA, not a patient dose form: Powder (26) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.

Allergan, Inc.11%
Somerset Therapeutics, LLC11%
Alembic Pharmaceuticals Inc.7%
Fosun Pharma USA Inc.7%
Akorn4%
Apotex Corp.4%
Other makers57%

Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

📈 How widely Bimatoprost is used

A general measure of how commonly Bimatoprost is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.

Think of this as a proxy for how widely Bimatoprost is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.

46,752
Medicaid prescriptions filled (Q1–Q4 2025)
$17.7M gross Medicaid reimbursement (before mandatory rebates — net cost is lower)

How commonly is Bimatoprost prescribed? Of the 1,596 medications we measure, Bimatoprost ranks #648 by Medicaid prescriptions — more than 59% of them.

Where Bimatoprost ranks among the drugs we measure · Q1–Q4 2025 · neighbors ±5

Utilization by Bimatoprost product

Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.

The 0.1 mg/mL ophthalmic solution is the most-dispensed Bimatoprost product — about 95% of these Medicaid prescriptions.

bimatoprost 0.1 MG/ML Ophthalmic Solution Most dispensed

44,447 Medicaid prescriptions (Q1–Q4 2025) 95% of Bimatoprost prescriptions shown $16.8M gross reimbursement (before rebates) ≈ $378 per prescription (gross)

Summed across the 3 of 12 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1009339

bimatoprost 0.3 MG/ML Ophthalmic Solution

1,758 Medicaid prescriptions (Q1–Q4 2025) 4% of Bimatoprost prescriptions shown $93,802 gross reimbursement (before rebates) ≈ $53 per prescription (gross)

Summed across the 10 of 29 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 308739

bimatoprost 0.01 MG Drug Implant

501 Medicaid prescriptions (Q1–Q4 2025) 1% of Bimatoprost prescriptions shown $862,248 gross reimbursement (before rebates) ≈ $1,721 per prescription (gross)

Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2286602

bimatoprost 0.3 MG/ML Topical Solution

46 Medicaid prescriptions (Q1–Q4 2025) <1% of Bimatoprost prescriptions shown $2,806 gross reimbursement (before rebates) ≈ $61 per prescription (gross)

Summed across the 2 of 9 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1041495

Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.

Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Bimatoprost, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 16 of 52 listed Bimatoprost NDCs with Medicaid activity.

🔍 Compare Bimatoprost products

A representative set of FDA-listed product records for Bimatoprost — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)

Showing 84 of 84 products — FDA National Drug Code Directory. See every product, package size and price: browse all 84 Bimatoprost NDCs →

RxNorm Concept Web — From Ingredient to Every Form and Strength

This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.

Ingredient (IN) Bimatoprost RxCUI 283810 4 dose forms · 5 strengths
  1. Dose form (SCDF) Drug Implant RxCUI 2286601 In current FDA listings
    Clinical drug / strength (SCD) 0.01 MG RxCUI 2286602
  2. Dose form (SCDF) Ophthalmic Gel RxCUI 2725167 In current FDA listings
    Clinical drug / strength (SCD) 0.0001 MG/MG RxCUI 2725168
  3. Dose form (SCDF) Ophthalmic Solution RxCUI 378341 In current FDA listings
    Clinical drug / strength (SCD) 0.1 MG/ML RxCUI 1009339 0.3 MG/ML RxCUI 308739
  4. Dose form (SCDF) Topical Solution RxCUI 1041494 In current FDA listings
    Clinical drug / strength (SCD) 0.3 MG/ML RxCUI 1041495

Look up RxCUI 283810 in the RxCUI Atlas →

RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.

🏷️ Sold under these brand names

Lumigan Latisse Durysta Zolymbus

🏭 Manufacturers & labelers

Allergan, Inc. 9 Somerset Therapeutics, LLC 9 Alembic Pharmaceuticals Inc. 6 Fosun Pharma USA Inc. 6 Akorn 3 Apotex Corp. 3 Lifestar Pharma LLC 3 Gland Pharma Limited 3 Sandoz Inc 3 Micro Labs Limited 2 Medisca Inc. 2 Letco Medical, Llc 2 NuCare Pharmaceuticals,Inc. 2 Industriale Chimica s.r.l. 2 Darmerica, Llc 2 Aurobindo Pharma Limited 2 Alembic Pharmaceuticals Limited 2 SciAnda(Changshu) Pharmaceuticals, Ltd. 1 Qingdao Biopeptek Co., Ltd. 1 ScinoPharm Taiwan Ltd. 1 Synergy Health AST, LLC 1 Piramal Healthcare (Canada) Limited 1 Thea Pharma Inc. 1 YS Life Science Co., Ltd. 1

…and 16 more on the FDA NDC directory.

RxNorm drug class

Bimatoprost belongs to the Prostaglandin Analog class.

Pharmacologic class Prostaglandin Analog
Drug family (ATC) Prostaglandin analogues

Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.

🔬 Where this comes from

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. ✓ Linked label effective Jul 1, 2024
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for Bimatoprost.
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.
🧾 Clinical label set — FDA-filed SPL labels retained for Bimatoprost after exact ingredient or ingredient-combination matching and applicable route/form matching
Clinical labels in scope
19
NDC products indexed
84
Distinct labelers/manufacturers represented
40
Linked representative label
Allergan, Inc.
Linked label effective
Jul 1, 2024
Composite sections available
21
Linked SPL Set ID
34f83d9d-2c64-463e-8a90-9a460fedfead
Linked SPL Document ID
f3f30669-e9b1-406b-b6fc-30c520f8ffb3
Open the linked representative label on DailyMed ↗

How we combine label and product data

HelloPharmacist combines public FDA and NLM records; we don’t author the underlying clinical facts. We identified 19 FDA-filed SPL label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. The representative label is the starting point for the displayed reference monograph; the 12 largest stored in-scope SPL records, which may include that representative, are compared section by section, and the longest available version of each section is retained. Forms, routes, brands, labelers, product-listed strengths, and product-record counts are aggregated separately from ingredient-matched FDA NDC Directory records; package records listed above are associated with the linked SPL; and the normalized concept hierarchy comes from NLM RxNorm.

For canonical ingredient pages, bounded product-attributed indication and administration excerpts may be added to the AI evidence, and the generator is instructed to preserve available product, brand, route, and form qualifiers instead of treating one label as universal. Where a section is identified as AI-written, its plain-language text is generated from bounded label evidence. New draft drug pages remain in the admin review queue before first publication. Allergan, Inc. is the representative DailyMed label linked for verification and dates; it is not the sole source used for the page.

This is general education, not medical advice — always consult your doctor or pharmacist about your medications and any medical condition. For the exact wording of the linked representative label, view that label on DailyMed; some displayed composite sections may come from other in-scope SPL labels. Learn how we use AI and our data sources & update cadence.